Drug reference
abiraterone acetate
CYP17A1 inhibitor · Steroidogenesis inhibitor
CYP17A1 inhibitorSteroidogenesis inhibitor
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
—
not curated
Mechanism
Abiraterone acetate is a CYP17A1 inhibitor.
Indications
prostate cancerendogenous cushing syndrome (under evaluation)reduction of adrenal androgen production in congenital adrenal hyperplasia (under evaluation)
Related guidelines
Ask House about abiraterone acetate
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team